Unlock instant, AI-driven research and patent intelligence for your innovation.
Phenylcarbamate compound and muscle relaxant containing the same
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A carbamate and carbamoyl technology, applied in the field of muscle relaxation compositions, can solve problems such as side effects
Active Publication Date: 2013-05-01
BIO PHARM SOLUTIONS
View PDF9 Cites 10 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, these drugs act on interneurons of the spinal cord, thereby inhibiting monosynaptic reflexes and polysynaptic reflexes, and thus may cause side effects such as central nervous system depression, muscle weakness, and the like
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
preparation Embodiment 1
[0079] Preparation Example 1: Synthesis of 1-(2-chlorophenyl)-trans-1-propene
[0080]
[0081] In a flask, 48 ml of 2-chlorobenzaldehyde (0.42 mol) and 49.7 ml of 3-pentanone (0.47 mol) were dissolved in 600 mL of hexane, and then stirred as the temperature increased. Add 53.6ml of borontrifluoride etherate (BF 3 OEt 2 , 0.42mol). When the reaction was complete, water was added thereto. After layer separation, the obtained organic layer was washed twice with 1M sodiumhydroxide solution (1M NaOH), and then the separated organic layer was washed with water. The separated organic layer was washed with anhydrousmagnesiumsulfate (MgSO 4 ) dehydrated and concentrated. The concentrated residue was purified by silica gelcolumn chromatography to give the title compound (38 g, yield 58%).
[0083] Preparation Example 2: Synthesis of 1-(2-chlorophenyl)-trans-1-butene
[0084]
[0085]Except for using 3-heptanone instead of 3-pentanone, substantially the same method as described in Preparation Example 1 was performed to obtain the title compound (2.9 g, yield 83%).
[0087] Preparation Example 3: Synthesis of 1-(2-chlorophenyl)-3-methyl-trans-1-butene
[0088]
[0089] Except for using 2,6-dimethyl-heptan-4-one instead of 3-pentanone, substantially the same method as described in Preparation Example 1 was carried out to obtain the title compound (8.0 g, yield 50-90%) .
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an active ingredient, and a method of muscle relaxation comprising administering a therapeutically effective amount of the phenylcarbamate compound, are provided.
Description
Background of the invention [0001] (a) Field of Invention [0002] The present invention relates to a novel phenyl carbamate compound and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a phenylcarbamate compound and a pharmaceutically acceptable salt thereof (the phenylcarbamate compound has a relatively high muscle-relaxing effect and low toxicity), and compounds containing the compound and / or or a pharmaceutically acceptable salt thereof as an active ingredient for muscle relaxation. [0003] (b) Description of related technologies [0004] Myotonia or spasms are often observed as sequelae of cerebrovascular disorders such as stroke or sequelae of traumatic brain injury and are not amenable to treatment. [0005] Myotonia or spasm is one of skeletal muscle dysfunction diseases due to increased muscle tone, and is caused by damage to the central nervous system due to various causes such as external injury, cerebrov...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.